Results 161 to 170 of about 84,180 (270)

Protectin D1 and maresin 1 attenuate airway hyperreactivity induced by IL‐13 in human isolated small bronchi

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 9, Page 2049-2060, May 2026.
Background and Purpose Interleukin (IL)‐13 is implicated in airway hyperreactivity (AHR), a key feature of asthma. We explored the potential anti‐AHR activity of selected specialised pro‐resolving mediators (SPMs) in IL‐13‐induced AHR models, using human bronchial smooth muscle cells (BSMCs) and human isolated bronchi.
Willem Abma   +9 more
wiley   +1 more source

Vesicular glutamate transporter VGLUT2 expression emerges in substantia nigra dopamine neurons in mouse models of parkinsonism in the absence of neurodegeneration

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 9, Page 2123-2138, May 2026.
Abstract Background and Purpose Subsets of midbrain dopamine (DA) neurons express the vesicular glutamate transporter VGLUT2 and can release the excitatory neurotransmitter glutamate. VGLUT2+ DA neurons of the substantia nigra pars compacta (SNc) were shown to be more resistant to neurodegeneration in animal models of Parkinson's disease (PD ...
Sivakumar Srinivasan   +2 more
wiley   +1 more source

A role for epithelium‐derived 6‐nitrodopamine on human ureter contractility

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 10, Page 2360-2375, May 2026.
Abstract Background and Purpose To investigate the basal release of 6‐nitrodopamine (6‐ND) from human isolated ureter and the role of this novel catecholamine in the ureter contractility. Experimental Approach Ureters from 67 brain‐dead organ donors (40 males and 27 females) were used during kidney transplantation procedures.
Wilmar Azal Neto   +12 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos   +16 more
wiley   +1 more source

The effect of inhaled dry salt on pulmonary mucociliary clearance in obstructive lung disease: A randomised, placebo‐controlled, crossover study

open access: yesClinical Physiology and Functional Imaging, Volume 46, Issue 3, May 2026.
Abstract Background Inhaled saline may improve mucus transport in respiratory diseases, for example, cystic fibrosis. This randomised, placebo‐controlled, crossover study examined the effect of inhaled dry NaCl on mucociliary clearance in patients with chronic obstructive pulmonary disease (COPD). Methods Twenty‐five patients with GOLD stage I‐III COPD
Rie Skovly Thomsen   +7 more
wiley   +1 more source

A Case of Constipation During Cobenfy Therapy and a Constipation Prevention Protocol. [PDF]

open access: yesCureus
Ezema EC   +8 more
europepmc   +1 more source

A Scoping Review of Non‐Opioid Therapeutics for Opioid Withdrawal: Translational Relevance to Neonatal Opioid Withdrawal Syndrome (NOWS) Research

open access: yesClinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT In the wake of the ongoing opioid epidemic, the incidence of neonatal opioid withdrawal syndrome (NOWS) has surged. While the short‐term effects of NOWS are well‐characterized, long‐term physiological and molecular consequences remain unclear.
Sara L. Mills‐Huffnagle   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy